Attana (ATANA) Q1 2025 earnings summary

Executive summary

• Focus on biosensor development and sales for biotech and pharma, with new research in borreliosis diagnostics presented at ESCMID Global 2025, highlighting broad applicability of the technology.

• Confirmed order from a German university, stemming from successful collaboration with a US university, whose research will be published in PNAS.

• CEO transition: Anna Hellergård appointed as new CEO from April 1, 2025; founder Teodor Aastrup becomes Head of Research.

Financial highlights

• Net sales for Q1 2025 were SEK 1.6 million, down from SEK 2.3 million in Q1 2024.

• Result after financial items improved to -SEK 0.4 million from -SEK 1.1 million year-over-year.

• Result per share improved to -0.0003 SEK from -0.0028 SEK year-over-year.

• Cash flow from operations was negative, with period-end cash at SEK -140,464.

Outlook and guidance

• Plans to capitalize on new research results in 2025 via increased instrument sales, licensing/partnerships, and analytical services.

• New marketing strategy implemented in Q2, focusing on digital visibility and targeted communication to drive growth.

• Commitment to accelerate commercialization and sales efforts with upcoming capital from TO2 options.